Virtus ETF Advisers’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-2,449
| Closed | -$68.1K | – | 277 |
|
|
2024
Q4 | $68.1K | Sell |
2,449
-1,292
| -35% | -$35.9K | 0.03% | 394 |
|
|
2024
Q3 | $107K | Buy |
3,741
+64
| +2% | +$1.84K | 0.05% | 366 |
|
|
2024
Q2 | $86.3K | Sell |
3,677
-202
| -5% | -$4.74K | 0.04% | 379 |
|
|
2024
Q1 | $98K | Sell |
3,879
-269
| -6% | -$6.8K | 0.05% | 368 |
|
|
2023
Q4 | $96.9K | Buy |
4,148
+2,353
| +131% | +$54.9K | 0.06% | 371 |
|
|
2023
Q3 | $90.8K | Sell |
1,795
-176
| -9% | -$8.9K | 0.06% | 346 |
|
|
2023
Q2 | $92K | Sell |
1,971
-318
| -14% | -$14.8K | 0.05% | 413 |
|
|
2023
Q1 | $87.6K | Sell |
2,289
-875
| -28% | -$33.5K | 0.05% | 367 |
|
|
2022
Q4 | $173K | Sell |
3,164
-9,817
| -76% | -$538K | 0.09% | 323 |
|
|
2022
Q3 | $442K | Buy |
12,981
+99
| +0.8% | +$3.37K | 0.18% | 221 |
|
|
2022
Q2 | $122K | Buy |
12,882
+5,080
| +65% | +$48.1K | 0.05% | 378 |
|
|
2022
Q1 | $111K | Sell |
7,802
-464
| -6% | -$6.6K | 0.05% | 286 |
|
|
2021
Q4 | $175K | Buy |
8,266
+1,120
| +16% | +$23.7K | 0.07% | 263 |
|
|
2021
Q3 | $160K | Sell |
7,146
-380
| -5% | -$8.51K | 0.07% | 326 |
|
|
2021
Q2 | $187K | Sell |
7,526
-2,928
| -28% | -$72.8K | 0.08% | 375 |
|
|
2021
Q1 | $303K | Buy |
10,454
+178
| +2% | +$5.16K | 0.13% | 238 |
|
|
2020
Q4 | $265K | Sell |
10,276
-2,410
| -19% | -$62.2K | 0.11% | 288 |
|
|
2020
Q3 | $391K | Sell |
12,686
-1,739
| -12% | -$53.6K | 0.21% | 173 |
|
|
2020
Q2 | $359K | Sell |
14,425
-2,632
| -15% | -$65.5K | 0.17% | 254 |
|
|
2020
Q1 | $362K | Sell |
17,057
-2,474
| -13% | -$52.5K | 0.15% | 206 |
|
|
2019
Q4 | $433K | Buy |
+19,531
| New | +$433K | 0.07% | 230 |
|